Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesCost Effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis
Applied Health Economics and Health Policy, 09/18/09
Earnshaw SR et al. – GA or NZ in RRMS patients is associated with increased benefits compared with symptom management, albeit at higher costs. Although year 1 and 2 disease progression and relapse rates were better for NZ than GA, long–term evidence may show GA to have similar, if not improved, clinical benefit.
Related Articles
Early Psychiatric Manifestation in a Patient with Primary Progressive Multiple Sclerosis
Archives of Iranian Medicine, 11/12/09
Relevance Score: 69%
Cochlear implantation in a profoundly deaf patient who also suffers from multiple sclerosis - a case study
Cochlear Implants International, 10/27/09
Relevance Score: 69%
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09
Relevance Score: 69%
Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis
International Immunology, 10/14/09
Relevance Score: 68%
Early Drug Treatment May Cut Multiple Sclerosis Risk
MedLinePlus, 10/08/09
Relevance Score: 68%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Methylphenidate on Cerebral Glucose Metabolism in Patients With Impaired Consciousness After Acquired Brain Injury
Clinical Neuropharmacology, 12/05/09
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Neuropharmacology, 12/05/09
Inhibition of long-term potentiation by valproic acid through modulation of cyclic AMP
Epilepsia, 12/05/09
Sponsor
Article Search
Sponsor